Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGS
$3.07
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-114.0M · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
41.8x
↑ROE
-12.7%
↓Gross Margin
14.5%
↓Debt/Equity
0.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.6%
FCF CAGR
—
FCF margin
-11.6%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $788.4M · net income $-103.5M · FCF $-91.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $788.4M | $788.4M | $797.0M | $781.4M | $751.4M |
| Net Income | $-103.5M | $-103.5M | $-196.1M | $-83.9M | $-175.7M |
| EBITDA | $27.2M | $27.2M | $-80.7M | $24.1M | $-57.6M |
| EPS | -0.29 | -0.29 | -0.56 | -0.23 | -0.49 |
| Gross Margin | 14.5% | 14.5% | 14.4% | 22.4% | 23.2% |
| Operating Margin | -7.1% | -7.1% | -9.9% | -3.4% | 2.8% |
| Net Margin | -13.1% | -13.1% | -24.6% | -10.7% | -23.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.55 | 0.55 | 0.47 | 0.56 | 0.43 |
| Current Ratio | 1.68 | 1.68 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-91.8M | $-91.8M | $-114.0M | $-179.6M | $24.5M |
| Returns | |||||
| ROE | -12.7% | -12.7% | -20.6% | -7.5% | -14.8% |
| Valuation | |||||
| EV/EBITDA | 41.85 | 41.85 | — | 147.63 | — |
| P/B | 1.34 | 1.34 | 1.66 | 3.08 | 2.54 |
| Growth & Yield | |||||
| Revenue Growth | -1.1% | -1.1% | 2.0% | 4.0% | — |
| EPS Growth | 47.7% | 47.7% | -136.2% | 52.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-22.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.56 → -0.29
Residual
-22.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.